Form 4: Vertex Pharmaceuticals EVP David Altshuler Reports Stock Transactions

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the acquisition and disposal of company stock, including transactions made under a pre-arranged trading plan.

Summary

• David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership of company stock.
• On February 24, 2025, Altshuler acquired 3,971 shares of common stock.
• These shares were acquired through the disposal of shares to cover tax obligations at a price of $483.28.
• On February 25, 2025, Altshuler sold 848 shares of common stock at a price of $480.95.
• Following these transactions, Altshuler beneficially owns 40,200 shares of Vertex Pharmaceuticals stock.
• The sale was executed under a company-approved trading plan (Rule 10b5-1) established on August 8, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Key Dates